News Brief
Summary
Merck reported strong Q3 earnings, beating estimates due to high demand for its cancer drug Keytruda. The company narrowed its full-year profit outlook, citing lower tariff costs and other factors. Keytruda sales exceeded $8 billion for the first time in a quarter. Merck is implementing cost-cutting measures and preparing for Keytruda’s patent expiration in 2028.
Key Points
- Q3 adjusted EPS: $2.58 vs. $2.35 expected
- Q3 revenue: $17.28B vs. $16.96B expected
- Keytruda sales: $8.14B, up 10% year-over-year
- 2025 adjusted EPS outlook narrowed to $8.93-$8.98
- Cost reduction target: $3B by end of 2027
- Gardasil sales down 24% due to lower demand in China
- Animal health sales up 9% year-over-year
新闻简报
总结
默克公司第三季度业绩强劲，得益于其抗癌药物Keytruda的高需求，盈利超出预期。公司收窄了全年利润展望，反映了较低的关税成本估算及其他因素。Keytruda季度销售额首次超过80亿美元。默克正在实施成本削减措施，并为Keytruda在2028年的专利到期做准备。
关键点
- 第三季度调整后每股收益：2.58美元，预期为2.35美元
- 第三季度营收：172.8亿美元，预期为169.6亿美元
- Keytruda销售额：81.4亿美元，同比增长10%
- 2025年调整后每股收益展望收窄至8.93-8.98美元
- 成本削减目标：到2027年底削减30亿美元
- Gardasil销售额下降24%，主因中国需求疲软
- 动物保健销售额同比增长9%
Original Article Link: https://www.cnbc.com/2025/10/30/merck-mrk-earnings-q3-2025.html